Alphabetical list:
A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9
News: November 23, 2009
Genetic Variant Slows AIDS Progression
November 23, 2009Scientists report that a genetic variation appears to play a major role in slowing disease progression in HIV-infected patients.
In fact, those with the variation appear to take years longer to develop AIDS and die of complications of the disease.
"We're honing in on factors that vary across individuals that make a person more or less susceptible to HIV, in terms of how rapidly someone develops the disease," said study co-author Mary Carrington, a senior principal investigator at the U.S. National Cancer Institute.
However, this new knowledge won't translate into immediate benefits for patients with HIV.
AIDS remains a major killer in many parts of the world, but HIV - the virus that causes it - doesn't affect infected people the same way. "People progress to AIDS at hugely different rates," Carrington explained. "Some people progress within a year, while some have been infected for 20 years and still control the virus and don't have the disease."
It appears that three factors affect how the disease strikes a person, she said. One is the environment: the world in which a person lives. Another is the patient's genetic makeup. And the third is the genetic makeup of the virus itself.
In the study, published in the Nov. 22 online edition of Nature Genetics, Carrington and colleagues looked at genetic and medical records for hundreds of HIV-infected men. They were trying to see if genetic variations affected how the men fared.
The researchers found that a variation linked to higher levels of a protein known as HLA-C boosted the men's ability to avoid progressing to AIDS. It appeared to delay both the progression to AIDS and to death by years, Carrington said.
The genetic variation makes it easier for the immune system to kill cells that have been infected with the virus, she said. It does this by allowing immune cells to gain greater access to the infected cells, she explained.
Carrington said this genetic variation isn't related to another gene-related trait that makes some people virtually immune to HIV.
The study "hints at ways we might ultimately develop a vaccine or immune-based therapies that could modify or maybe even prevent the development of HIV disease," said Rowena Johnston, vice president of research with the Foundation for AIDS Research in New York City.
"The finding that a single piece of DNA can be strongly associated with something as complex as the control of HIV soon after infection is especially intriguing, not least because we know that early control of infection sets the stage for the entire course of the disease," Johnston noted.
What's next? The ultimate goal, Carrington said, is "to have a complete list of every genetic variance that is affecting how rapidly the disease develops."
That, in turn, could help physicians figure out how to better treat patients.
Archive issues: (50)
Archive list: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 [16] 17
October 17, 2011 | Sen. Grassley Seeks FDA Scrutiny of Paxil and Suicide RiskWASHINGTON, June 12, 2008 Senator Chuck Grassley has asked the Food and Drug Administration to carefully scrutinize information it received from drug maker GlaxoSmithKline about the anxiety disorder drug Paxil, based on the contents of a newly available report about the drug's risk for suicide among adults. Grassley also asked the FDA to ...
September 21, 2009 | Topical cream studied for erectile dysfunctionScientists from Albert Einstein College of Medicine of Yeshiva University are working on a cream to rub on and treat erectile dysfunction (ED). The cream could prove to be safer than oral medications used to deliver nitric oxide ...
May 21, 2012 | Onyx Rises on Analyst View of Blood Cancer DrugNEW YORK -- Onyx Pharmaceuticals Inc. shares rose Thursday after a Bernstein Research analyst started covering the stock with an "Outperform" rating, saying he thinks the company’s blood cancer drug candidate will reach $1 billion in annual sales by ...
Related articles:
Chronic prostatitis/chronic pelvic pain syndrome - prevalence
The annual prevalence in the general population of chronic pelvic pain syndrome is 0.5%. 38% of primary care providers, when presented with a vignette of a man with CPPS, indicate that they have never seen such a patient. However, the overall prevalence of symptoms suggestive of CP/CPPS is 6.3%. The role of the prostate was questoned in the etiology of CP/CPPS when both men and women in the general population were tested using the (1) National Institutes of Health Chronic Prostatitis Symptom Index ...Section: Prostatitis
Chronic bacterial prostatitis - signs and symptoms
Chronic bacterial prostatitis is a relatively rare condition - occurs in less than 5% of patients with prostate-related non-BPH lower urinary tract symptoms (LUTS) - that usually presents with an intermittent UTI-type picture and that is defined as recurrent urinary tract infections in men originating from a chronic infection in the prostate. Dr. Weidner, Professor of ...Section: Prostatitis
Chronic prostatitis/chronic pelvic pain syndrome - signs and symptoms
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is characterised by pelvic or perineal pain without evidence of urinary tract infection, lasting longer than 3 months, as the key symptom. Symptoms may wax and wane. Pain can range from mild discomfort to debilitating. Pain may radiate to back and rectum, making sitting difficult. Dysuria, arthralgia, myalgia, unexplained ...Section: Prostatitis